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ABSTRACT
In this dissertation we present rule-based machine learning methods for solving problems
with high-dimensional or complex datasets. We are applying decision tree methods on bloodbased biomarkers and neuropsychological tests to predict Alzheimer’s disease in its early stages.
We are also using tree-based methods to identify disparity in dementia related biomarkers among
three female ethnic groups. In another part of this research, we tried to use rule-based methods to
identify homogeneous subgroups of subjects who share the same risk patterns out of a
heterogeneous population. Finally, we applied a network-based method to reduce the
dimensionality of a clinical dataset, while capturing the interaction among variables. The results
show that the proposed methods are efficient and easy to use in comparison to the current machine
learning methods.
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CHAPTER 1: INTRODUCTION
Although an abundance of biomarkers can be measured in large-scale studies such as
TEDDY/ADNI, it is unrealistic to measure all these biomarkers in the general population, due to
the high cost, rigorous preprocessing and standardization protocols, and limited feasibility.
Therefore, to proliferate outside the research arena, a risk monitoring system must be costeffective, easy to implement and efficient for repeated use.
In this dissertation we target problems by identifying risk-predictive rules and also
selecting and assembling the rules. So, the first problem is to generate rules from data and then
optimally select and assemble a compact set of rules for accurately monitoring disease progression.
The key for successful adoption of existing rule-discovery algorithms, when analyzing datasets
with a large number of variables and interactions is to reduce the number of variables beforehand.
While most existing high dimensional feature selection methods aim to identify the significant
features, rule discovery concerns a more difficult problem that involves not only the
features/variables (we will use the terms interchangeably) themselves, but also their interactions
and ranges, which exponentially increases the dimensionality of the problem. Thus, the essential
computational challenge is to identify highly synergistic groups of features such that high-quality
rules are more likely to be discovered. To address this challenge, we propose to investigate a novel
screening paradigm via a series of ensemble rule methods.
In the second chapter of this dissertation, we discuss trying to predict the elevation of brain
amyloid burden using neuropsychological tests and blood-based biomarkers. Elevated brain
1

amyloid burden is the first symptom of Alzheimer’s disease onset and we are applying decision
tree models to predict that. To the best of our knowledge, there has not been any research,
investigating Alzheimer’s disease onset using a combination of neuropsychological tests and
blood-based markers.
In the third chapter, we developed decision tree models to investigate plasma biomarkers
of mild Alzheimer’s Disease in females from three different ethnic groups. We tried to identify
rules characterizing progression patterns in Hispanic, African American and Caucasian females.
We used pathologic, inflammatory and cardiovascular markers measured in the plasma samples.
The study tries to compare disease progression pattern in three different ethnic groups of females.
In Chapter four, we used the RuleFit algorithm to characterize homogeneous subgroups of
subjects who participated in a pediatric study. We tried to find rules that identify subgroups with
different risk patterns of parents who withdrew from The Environmental Determinants of Diabetes
in Young (TEDDY) study in the first year. We analyzed the dataset from the survey which was
filled out by parents at the inception of the study and identified eight predicting rules to predict
withdrawal from the study.
In Chapter Five we tried to predict the progression pattern towards Alzheimer’s disease,
while doing dimensionality reduction using a network based system. We used the RuleFit
algorithm to generate rules and the Latent Trait model for weighting the rules. Finally, we used
the network based algorithm to select the most synergistic set of rules. In this study we tried to
find fewer neuropsychological tests to administer, instead of a battery of 16 tests which take around
four hours.

2

CHAPTER 2: IDENTIFYING COST-EFFECTIVE PREDICTIVE RULES FOR
AMYLOID-β LEVEL BY INTEGRATING NEUROPSYCHOLOGICAL TESTS AND
PLASMA-BASED MARKERS 1
2.1

Introduction
Alzheimer’s disease (AD) is a progressive, fatal neurodegenerative disorder, characterized

by memory loss and other cognitive impairments. There is now a scientific consensus that the
pathological events in AD initiate decades before clinical symptoms become apparent, and diseasemodifying therapies will be most effective at the earliest stages of the disease. A major diseasemodifying therapy which holds great promise in preventing AD is anti-amyloid preventative
treatment [2], since abnormal amyloid-β deposition has been widely regarded as the initial event
in a cascade of pathological processes, leading to synaptic dysfunction and neuronal death, and
followed by the development of cognitive impairment and eventually dementia [3]. Despite the
promises held by the developing anti-amyloid preventative treatments, the success of their clinical
trials requires appropriately selected participants who are positive for Aβ pathology.
The identification of suitable individuals with elevated brain amyloid burden poses a great
challenge in terms of feasibility and cost. To date, the advancement of molecular imaging tracers
that bind to amyloid, such as the Pittsburgh Compound B (PiB), offers a non-invasive in vivo
method to detect and quantify brain amyloid deposition [4,5]. However, this approach for pre-

1
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symptomatic detection is economically challenging for routine use given the current cost [6].
Similarly, the clinical use of other useful biomarkers such as Aβ 1-42 and phosphorylated tau in
cerebral spinal fluid (CSF) is also limited, since lumbar puncture carries risks and is met with
resistance in elderly subjects. Further it is unlikely to be used in primary health care centers to
routinely screen large number of participants. Given the cost and limited availability of these brain
amyloid measurement techniques, they are not reasonable first-line approaches for screening
participants at risk of having elevated brain amyloid burden.
Recent studies have revealed the possibility of predicting elevated brain amyloid burden
using more cost-effective measurements, such as neuropsychological tests and blood-based
biomarkers. Some concurrent relationships between Aβ and cognition [7-9], metabolism decline
[10] and brain atrophy [11], have been identified. A few studies have developed models to predict
elevated Aβ level or Alzheimer’s Disease, using either neuropsychological measures [12,13] or
blood-based markers [14-17]. On the other hand, although neuropsychological measures and
blood-based biomarkers have more practical applicability for routine use and are more cost
effective, their predictive capabilities for detection of pre-symptomatic Alzheimer’s disease are
still limited [12-17]. For instance, by relying on neuropsychological measures alone, individuals
with very high premorbid intellectual abilities experiencing incipient cognitive decline may go
undetected, and false positives are possible in individuals with a low level of intellectual ability. It
is also a well-known fact that the ceiling and floor effects limit the measurement capacity of many
neuropsychological instruments [18-20]. Also, the set of blood-based biomarkers that have been
reported as associated with AD are largely inconsistent in the literature [14-17], probably due to
the inherent measurement uncertainty since these markers fluctuate over time [21,22]. Another
possible reason is that uni-variate statistical methods were used for identifying these blood-based
4

biomarkers, falling short of recognizing the multivariate patterns that may be more robustly and
reliably associated with AD pathology [14-17].
To date, we are aware of no prior work that has explicitly sought to identify these
multivariate patterns which integrates both neuropsychological tests and blood-based markers, as
existing research works focus on either neuropsychological tests or blood-based markers alone. As
it is becoming increasingly apparent that uni-variate biomarkers are not sufficiently sensitive or
specific for the diagnosis of complex, multifactorial disorders such as AD [23], it is more
promising to consider applying multivariate data mining approaches to combine the
neuropsychological measures and blood-based biomarkers and allow them to complement with
each other, in order to identify biomarker signatures which are consistent with pre-clinical AD and
specifically associated with amyloid pathology. Such an approach will be more practical for
clinical use and be germane in designing large-scale prevention trials by enriching for those cases
that are more likely to be amyloid positive by PET imaging. This would then require smaller
numbers of individuals to be screened to populate anti-amyloid secondary prevention trials.
Therefore, our aim is to investigate the feasibility of extracting cost-effective, simple
predictive rules of brain amyloid-β positivity for enriching the study population for clinical trials
of anti-amyloid treatments, by integrating the neuropsychological tests and blood-based markers.
We explore different strategies for building our prediction models, and compare their predictive
performances. Moreover, rather than focusing on predictive regression models as in most of the
relevant existing studies [12-17], we use the decision tree model since it can lead to simple decision
rules that can be naturally translated into clinical settings for detecting amyloid positive cases.
Furthermore, these rules will permit some individuals to be classified on the basis of only one, or

5

at most a few, measurements, whereas scores derived from regression-based prediction models,
such as logistic regression or support vector machine, require that all covariates are available.
2.2
2.2.1

Materials and Methods
Subjects
All data used in the preparation of this article were obtained from the ADNI database

(adni.loni.ucla.edu). ADNI is a naturalistic, longitudinal study of AD onset and progression being
conducted at 57 sites in the United States and Canada. The ADNI was launched in 2003 by the
National Institute of Aging (NIA), the National Institute of Biomedical Imaging and
Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical
companies, and non-profit organizations. Further information about ADNI can be obtained from
www.adni-info.org.
2.2.2

Analysis Dataset
Data used for the analyses presented here were accessed on May 11 2013 and comprise

data from 50 normal adults aged 65 and older and 168 age-matched MCI (mild cognitive
impairment) subjects for which blood proteomics data and Aβ status were available. Normal
individuals were free of memory complaints or depression and had a Mini-Mental State
Examination (MMSE) score of 28 to 30 and a Clinical Dementia Rating (CDR) score of 0. MCI
individuals met Petersen criteria for single-domain or multi-domain amnestic MCI with MMSE
scores of 24 to 27, CDR of 0.5, and an informant-verified memory complaint substantiated by
abnormal education-adjusted scores on the Wechsler Memory Scale Revised—Logical Memory
II. Other cognitive domains and everyday functioning were intact.

6

The variables included in this study are as follows. For neuropsychological measurements,
we used the standard 11-item version of the ADAS - cog (including: word recall, commands,
construction, naming, ideational praxis, orientation, word recognition, recall instructions, spoken
language, word finding, comprehension) and 2 additional items (delayed word recall and number
cancellation). We also included the individual total scores from both the 11-item and 13-item
versions. For blood-based markers, we used the proteomics data set that was produced by the
Biomarkers Consortium Project “Use of Targeted Multiplex Proteomic Strategies to Identify
Plasma-Based Biomarkers in Alzheimer's Disease” [24]. We used 146 blood-based markers from
the proteomic data downloaded from the ADNI web site. For measurements of amyloid burden,
we used both PiB-PET imaging and CSF beta amyloid 1–42 (Aβ 1-42) level. The subjects were then
dichotomized into either PiB positive (PiB retention summary measure > 1.5) or PiB negative (PiB
retention summary measure ≤ 1.5), based on a threshold used in [25]. The CSF samples were
acquired from these subjects by the ADNI Biomarker Core laboratory at the University of
Pennsylvania Medical Center. The subjects were then dichotomized into either CSF Aβ 1-42 positive
(CSF Aβ1-42 level of ≤ 192 pg/mL) or CSF Aβ1-42 negative (CSF Aβ1-42 level of >192 pg/mL),
based on a threshold used in [26]. Finally, a subject is classified as amyloid positive if the subject
is positive either by PiB-PET or CSF Aβ1-42 or both.
2.2.3

Statistics
Data for the 50 normal and 168 MCI were used for building the prediction models. As

mentioned in the introduction, we explored different strategies for integrating the
neuropsychological tests and blood-based markers, and compared the predictive performance of
these integrated prediction models with the single-modality prediction models that are built on
either neuropsychological tests or blood-based markers. Specifically, we: 1) evaluated the
7

predictive performance of the neuropsychological measurements; 2) evaluated the predictive
performance of the blood-based biomarkers; 3) evaluated the predictive performance when the
neuropsychological measurements and blood-based biomarkers were combined.
Therefore, we generated three decision tree models: model 1 (M1) built a decision tree that
only uses the ADAS-cog; model 2 (M2) built a decision tree that only uses blood-based markers;
model 3 (M3) built a decision tree that uses both ADAS-cog and blood-based markers. For creating
each of the decision tree models, the conditional recursive partitioning technique [27] was used.
This technique is a nonparametric methodology that creates a decision tree with respect to risk
factors and their interactions that are most important in determining the outcome. Basically, it
consists of three steps. The first step is tree building. A group of subjects (represented as a node
on the tree) would split into child nodes if the testing statistic that measures the group differences
between the two child nodes was significant for any feature beyond the 0.05 probability level. The
significance level was adjusted for the number of multiple comparisons by the Bonferroni method.
The cut-off point that determined the splitting of the node for a continuous variable was the point
that maximized the test statistic with the P value less than 0.05. Each split resulted in the definition
of two subgroups. The second step is termination of the tree building. There are multiple criteria
that have been demonstrated to be effective in the termination of tree building. One approach that
was adopted in our study was to terminate the tree building when there were a minimum prespecified number of observations in each of the leaf nodes, i.e., 30 observations was used in our
study. The third step was tree pruning that revised and reduced the size of the obtained tree after
step 2. The main purpose of tree pruning was to achieve the optimal balance between the tree
complexity (i.e., a tree with too many levels and leaf nodes will be cumbersome to use) and
maintenance of prediction accuracy, (by deleting the internal nodes that do not substantially
8

improve accuracy). A simple but effective strategy recommended in the literature is to select the
smallest tree whose model error falls within the one standard error rule [27], which was adopted
in our study also. Decision tree analysis has been found valuable in many biomedical studies. For
example, it was used for a cancer study to divide patients into homogenous groups based on the
length of survival [28]. It has an advantage over the regression models in identifying prognostic
factors because it relies on fewer modeling assumptions and has an established procedure that
adapts to missing data through the use of surrogate measures. Also, because the method is designed
to divide subjects into groups based on the heterogeneity of clinical outcome of interest, it defines
groupings for outcome classification whereas regression models do not. Moreover, there is no need
to explicitly include covariate interactions or transformations because of the recursive splitting
structure of tree model construction. Analyses were performed using R, version 2.12
(http://www.r-project.org/), and the contributed libraries for our analyses, were “party”, and
“pROC”.
2.2.4

Evaluation of Predictive Performances of Different Models
In attempt to evaluate the predictive performances of these models, we use both internal

and pseudo-external validation. First, we randomly split the whole dataset into 2 subsets of twothirds and one-third size. The first two-thirds dataset will be used for internal validation, and the
one-third dataset will be used for pseudo-external validation.
For the internal validation, a 5-fold cross-validation procedure was used to randomly divide
the two-third dataset into 5 equal sized parts. Then each part was left out as the internal testing
dataset one at a time, and the remaining 4 parts were used as a training set to train the decision tree
model, which was used to predict on the internal testing dataset. After all 5 iterations were finished,
the predictions from all 5 test sets were pooled together to estimate the classification accuracy,
9

sensitivity, and specificity. This entire procedure on the two-thirds dataset was repeated 10 times,
with different initial seeds, to yield robust estimates of the classification accuracy, sensitivity and
specificity. Sensitivity refers to the ability to correctly classify the subjects who are amyloid
positive; it measures the proportion of amyloid positives who are correctly identified as such.
Specificity refers to the ability to correctly classify the subjects who are amyloid negative and
measures the number of amyloid negatives who are correctly identified as such.
The external validation was conducted upon the one-third dataset once a decision tree
model was built from the two-thirds dataset. This division resulted in similar numbers of control/
MCI and amyloid positive/negative cases in the train and test sets. The decision tree model was
applied to the one-third dataset, and thereby, the classification accuracy, sensitivity, and specificity
of the three models was estimated.
2.3
2.3.1

Results
Demographics
Characteristics of the 218 participants that are used in our study are summarized in Table

1 (so are the characteristics of the training and testing dataset that are generated by randomly
splitting the 218 participants). Participants are well matched for age (P=0.4866, Kruskal-Wallis
test) and education. There are more men than women (60.0%, 71%, for Normal and MCI,
respectively), and the proportion of men is greater in the MCI group.
2.3.2

Estimation of the Three Models Based on the Training Dataset
The three models were built using two-thirds of the data for training. The estimated model

of M1, using only the cognitive function data, is shown in Figure 1, together with the classification
results of all 218 subjects (including both the training dataset and testing dataset). Here, M1
10

identified 3 variables from the ADAS-cog tests, which are Delayed Word Recall, Orientation, and
the TOTALMOD (The modified ADAS-Cog 13-item scale includes all original ADAS-Cog items
with the addition of a number cancellation task and a delayed free recall task, for a total of 85
points. [29]). M1 identified two highly enriched subgroups, Node 1 (majority is amyloid negative)
and Node 5 (majority is amyloid positive). These two subgroups are characterized by two rules,
M1_Rule1: TOTALMOD ≤ 7.33 -> amyloid negative, M1_Rule2: (TOTALMOD > 13.67 AND
Delayed Word Recall >6 AND Orientation >0) -> amyloid positive. Note that, Node 4 also has a
relatively homogenous subgroup where the majority is amyloid positive.
The model M2 (as shown in Figure 2) automatically identified 5 blood-based markers that
were predictive of the amyloid-positivity out of the 146 blood-based markers. These 5 markers are
APOE (Apolipoprotein E), PAP (Prostatic Acid Phosphatase), TTR (Transthyretin), MMP10
(Matrix Metalloproteinase-10) and MYOGLOBN (Myoglobin). M2 also identified two highly
enriched subgroups, Node 1 (majority is amyloid negative) and a merger of Node 5 and Node 6
(majority is amyloid positive). These two subgroups are characterized by two rules, M2_Rule1:
(APOE > 1.785 AND TTR > 2.569) -> amyloid negative, M2_Rule2: (APOE ≤1.785 AND PAP
≤ - 0.638 AND MMP10 > - 1.481) -> amyloid positive.
Model M3 (as shown in Figure 3) used all the ADAS-cog variables and the blood-based
markers as potential predictors. It identified one ADAS-cog variable, the TOTALMOD, and three
blood-based markers, the APOE (Apolipoprotein E), FSH (Follicle-Stimulating Hormone) and
IGM (Immunoglobulin M), which were predictive of cases that were the amyloid pathology. M3
identified three homogenous subgroups, Node 1 (majority is amyloid negative), Node 4 (majority
is amyloid positive) and Node 5 (majority is amyloid positive). These three subgroups are
characterized by three rules, M3_Rule1: (TOTALMOD≤ 13.67 AND IGM>0.176) -> amyloid
11

negative, M3_Rule2: (TOTALMOD>13.67 AND FSH≤ 1.079 AND APOE≤ 1.69) -> amyloid
positive, M3_Rule3: (TOTALMOD > 13.67 AND FSH > 1.079) -> Amyloid Positive.
2.3.3

Performance Evaluation of the Three Models Using the Internal Validation
The sensitivities, specificities and the AUC values of all the three models that are obtained

by both the internal cross-validation and pseudo-external validation are shown in Table 2. From
the internal validation results, it is evident that M3 has the maximum predictive capability since
its AUC, sensitivity and specificity are all larger than other models. This indicates that an
integration strategy tends to produce better prediction model than the simple strategy that is used
by M1 and M2. Comparing M1 with M2, it can be seen that M1 has larger prediction capability
than M2, in terms of the mean values of the AUC, sensitivity and specificity. Note that M1 is a
decision tree model based on ADAS-cog, while M2 is a decision tree based on blood-based
markers. However, the difference between M1 and M2 is not statistically significant considering
the standard derivations of the performance values. All these observations hold on the pseudoexternal validation results.
2.3.4

Application of the Three Models to the Pseudo-External Validation Dataset
All the three models were estimated using the two-third training dataset. The remaining

one-third testing data was used to evaluate their predictive performances. The results are shown in
Figure 4. It is evident that all the models were predictive of the testing data, showing that overfitting is thereby not likely. It can also be seen that the prediction performance of M3 is superior
to the other models, i.e., the 95% CI of the AUC of M3 doesn’t overlap with the 95% CI of the
AUC of M1 and M2, which demonstrated that the integration of both the neuropsychological tests
with blood-based markers is effective. The sensitivity and specificity can also be extracted by
analyzing Figure 4. For example, with the specificity being fixed at 0.75, the sensitivities of the
12

three models are approximately 0.61, 0.56, 0.77, respectively. Note that our cross-validation
randomly split the whole dataset into two subsets without intentionally balancing the subsets for
amyloid positivity, yet maintained a similar distribution of positive and negative cases (see the
characteristics in Table 1).
2.4

Discussion
Our study identified effective prediction models for detecting subjects with elevated

amyloid burden. All three models identified simple rules that are predictive of brain amyloid level.
(These rules use cost-effective measurements, and also permit some individuals to be classified on
the basis of only one, or at most a few, measurements. For example, in M2 (Figure 2), 43% of the
216 subjects have the ApoE plasma value > 1.785, and only 33% of this group are amyloid positive.
In contrast, 57% of the 216 subjects have the ApoE plasma value ≤ 1.785, and 67% of this group
are amyloid positive. This implies that by implementing the decision rule, ApoE ≤ 1.785 ->
amyloid positive, it will enrich the amyloid positive population two fold. Therefore, as long as
these rules can be clinically validated, we believe that these simple decision rules can be naturally
translated into clinical settings, such as enrichment screening for Alzheimer’s prevention trials of
anti-amyloid treatments. The black area in each box plot at the end of terminal nodes shows the
percentage of amyloid positives; the number of subjects in each terminal node is included at the
top of the nodes. The trees were shown to be unchanging through cross-validations, since the
algorithm used for tree building in our study is based on CTREE (Conditional Inference Tree)
which results in unchanging trees in comparison to traditional decision trees. Since the CTREE
conducts multiple test procedures to fulfill the stopping criteria, while the traditional decision trees
apply information measures such as the Gini index.
13

Some comments on the M1 decision tree model that only uses ADAS-cog variables. It is
evident from the tree (shown in Figure 1) that, the risk of being amyloid positive increases from
the left nodes to the right nodes, while at the same time, the scores of the ADAS-cog items that
are used by M1 also increase. This trend is consistent with the nature of ADAS-cog as higher
scores of the ADAS-cog variables imply greater cognitive impairment. Also, the item, delayed
word recall, has been found to be associated with amyloid pathology in recent studies that used
cohorts of cognitively normal subjects which were different from ours [8,30]. On the other hand,
the correlation between the ADAS-cog items, the “orientation”, with amyloid pathology, requires
further investigation.
The interpretation of the result in Figure 4, i.e., that M1 slightly outperforms M2, needs to
be interpreted cautiously. First of all, the difference between the prediction performance of M1
and M2 is not statistically significant. Secondly all, M1 has lower specificity than M2 (Table 2).
Thirdly, the prediction performance of M1 may be biased towards higher accuracy, since ADAScog has been used as a major criterion in ADNI for defining the diagnostic groups, and there is a
significant correlation between the clinical diagnosis (e.g., defines MCI or NC) with amyloid
positivity in our cohort (p-value < 0.05). So, it is biased to use the neuropsychological
measurements to predict the outcome, because for some subjects the outcomes were defined by
these neuropsychological measurements.
An integration of ADAS-cog with blood-based markers improved the prediction accuracy.
From Figure 4, it is clear that the integrative model, M3, outperforms M1 (ADAS-cog only) and
M2 (blood-based markers only). This implies that the ADAS-cog and blood-based markers provide
supplementary predictive information.
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The blood-based markers that are found predictive of the amyloid deposition are ApoE
(Apolipoprotein E), PAP (Prostatic Acid Phosphatase), TTR (Transthyretin), MMP10 (Matrix
Metalloproteinase-10), MYOGLOBN (Myoglobin), IGM (Immunoglobulin M) and FSH (FollicleStimulating Hormone). Most of these blood-based markers have been found to be associated with
amyloid pathology or Alzheimer’s in previous studies. For example, the association between the
APOE level in plasma with brain amyloid burden has been identified in [17,31,32], where
Thambisetty et al. [32] used the BLSA cohort that is a different cohort from ours. Our result is
consistent with the studies in [17,31,32] that showed that the level of APOE in plasma, independent
of genotype, is also a marker of risk. The PAP, as an amyloidogenic protein, has been found to
form amyloid fibrils independent of those formed by Aβ [33]. The IGM has been reported in [34]
to be protective in Amyloid formation since they may serve as a “buffering system” to keep free
potential toxic endogenous peptides. This protective effect is also consistent with the results in M2
(shown in Figure 2), i.e., the subgroup of node 2, who have a lower level of TTR, is more likely
to be amyloid positive than the subgroup with higher level of TTR (node 1) since TTR binds with
amyloid-β (Aβ) and has been suggested to protect against Aβ deposition [35]. So, node 1, which
has higher level of TTR, has the expected lower number of amyloid positive subjects. Also, the
evidence shows that matrix metalloproteinases (including the MMP10) play an important role in
the pathogenesis of AD and may be involved in the processing pathway of amyloid beta [36]. It
has been shown that the chromogranin peptides are markers for human hippocampal pathways,
and have a potential as neuronal markers for synaptic degeneration in Alzheimer's disease [37].
Evidence that supports the associations between FSH and MYOGLOBN with the amyloid
pathology can be found [38,39].
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We also compared our results with the 16 blood-based markers found to associated with
brain amyloid burden in [17], and found only the association of APOE with amyloid is mutual. As
that study employed a uni-variate linear regression model for identifying the blood-based markers
on the ADNI cohort, the associations between the 16 blood-based markers with amyloid burden
were reported to be quite weak [17]. These associations were not significant after adjusting for
other covariates such as age. On the other hand, our method identified a different set of bloodbased markers that were highly predictive of amyloid burden when used in combination as rules,
indicating that our method has the advantage of identifying the blood-based markers that are
correlated with amyloid pathology in a nonlinear and multivariate way.
Our study has limitations. First, we only used the ADAS-Cog as the representative
neuropsychological measurement. Although ADAS-Cog is a standard tool in pivotal clinical trials,
those intended to provide evidence for a drug marketing approval, to detect therapeutic efficacy in
cognition, it is not considered sensitive enough to measure disease progression in early disease
stages. As our ultimate goal is to identify an enrichment decision model for detecting amyloid
positive cases from cognitively normal subjects, a better alternative may be the
Neuropsychological Test Battery [40]. Also, since our study relied on one single cohort for
estimating and validating the decision tree model, whether the enrichment decision model can be
generally applied to other research studies remains to be confirmed. Moreover, we used both
normal aging and MCI subjects for analysis, whether the decision tree models can extrapolate to
general normally aging subjects needs to be further validated.
Our future work includes a large-scale study that will use all the potential clinical variables
rather than ADAS-cog only. We will include a number of AD-related neuropsychological
measurements, such as MMSE, Boston Naming Test, Verbal Learning Test, Clinical Dementia
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Rating scale, to name a few. Three recent studies have revealed that some of these
neuropsychological measurements are predictive of amyloid pathology [12,13,41]. Existing
research has also revealed that some variables measuring the activities of daily living are also
associated with the Alzheimer’s [42]. We need to validate our enrichment decision model on other
cohorts. Moreover, although the integration model, M3, has demonstrated its effectiveness, it is
possible that a better integration strategy may exist, which can further boost the prediction
accuracy. Overall, the results indicate that the neuropsychological measurements with blood-based
markers can lead to an effective and accurate prediction model for detecting subjects with elevated
amyloid burden. This prediction model has led to several simple rules, which have a great potential
for use in clinical settings, such as enrichment screening for Alzheimer’s prevention trials of antiamyloid treatments.
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Table 1 Demographics of the 218 participants
Number
AGE
Education
Gender (% male)
MMSE

NC (Total)
50
83.82(6.3)
15.9(3.03)
0.6

29.28(0.93)

MCI
(Total)
168
82.06(6.9)
16.2(2.56)
0.71

26.98(1.99)

Training
NC
37
85.32(5.2)
15.8(3.0)
0.59

29.16(0.93)

Training
MCI
108
81.5(6.9)
16.2(2.6)
0.71

26.98(1.99)

Validation
NC
13
79.5(7.6)
16.3(3.1)
0.62

29.62(0.87)

Table 2 The prediction performance statistics of the three models
Model
M1
M2
M3

Sens % (s.d. %)
0.71 (0.07)
0.63 (0.04)
0.71 (0.05)

Internal Validation
Specs % (s.d. %)
AUC % (s.d. %)
0.65 (0.05)
0.79 (0.04)
0.67 (0.06)
0.75 (0.02)
0.68 (0.06)
0.82 (0.02)

27(2.01)

Pseudo-External Validation
Sens % Specs % AUC %
0.71
0.67
0.77
0.65
0.68
0.74
0.69
0.72
0.85

Figure 1 The decision tree model of ADAS-cog (M1)
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Validation
MCI
60
83.1(7.0)
16.2(2.6)
0.72

Figure 2 The decision tree model of blood-based markers (M2)

Figure 3 The decision tree model of both ADAS-cog and blood-based markers (M3)
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Figure 4 The receiver operator curves of the three models on the testing dataset
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CHAPTER 3: THE DISPARITY OF DEMENTIA RELATED PLASMA BIOMARKERS
AMONG ETHNIC MILD AD FEMALE PATIENTS
3.1

Introduction
The new criteria and guidelines for diagnosis of Alzheimer’s Disease (AD) highlight the

importance of identifying the need for biomarkers that are specific and sensitive to identify the
disease in its early stages. In recent publications, patients’ cerebral spinal fluid (CSF) has been
used to identify specific biomarkers that predict AD progression [43]. For example, studies
performed on CSF samples identified increased expression of both total tau and phosphorylatedtau specific to AD patients compared to the normal controls [44]. In addition, studies have linked
low levels of amyloid beta 42 (Aβ42) in CSF with AD progression, highlighting the specificity of
Aβ42 as a CSF biomarker [44]. Although studying relevant AD biomarkers provide promising
diagnostic and therapeutic potential, CSF collection is an invasive and expensive method [44]. The
utilization of biological samples such as plasma, which are routinely collected during patients’
clinical visits, represents a more feasible option and would help facilitate early discovery of AD
biomarkers [43,45].
Although the pathological biomarkers (amyloid beta and tau levels) are important early
indicators of AD disease progression, supplemental cardiovascular and inflammatory biomarkers
would allow for a more effective early diagnosis. Despite the association of cardiovascular risk
factors with the increased risk of Alzheimer’s Disease in the African American population [46],
few studies have focused on the neuro-pathological association between cardiovascular risk factors
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and AD in this population [46-48]. In addition, few studies have been performed entailing
inflammatory markers as potential biomarkers in AD disease progression, despite laboratory
research and genome wide association studies (GWAS) recognizing the impact of inflammation
on AD pathology [49-51]. According to Alzheimer’s Association reports, African Americans are
twice as likely and Hispanics are about one and one-half times more likely to have Alzheimer’s
disease (AD) compared to Caucasians (Alzheimer Organization Association, 2012). Also, risk
factors such as high blood pressure, diabetes [52] and gender [53,54] are associated with
Alzheimer’s disease and other dementias [55]. There are no known genetic factors explaining the
increased prevalence in African American and Hispanic communities; however, the
aforementioned conditions are more prevalent in these groups [56]. Most longitudinal and cross
sectional studies lack analyses of the role minority patients play in Alzheimer’s disease studies.
Our study aims to identify specific vascular, inflammatory and pathological plasma
biomarkers that are significantly associated with the incidence of Alzheimer’s disease in female
patients. Moreover, we aimed to identify biomarkers that specifically link the incidence of mild
AD to African Americans compared to Hispanic and Caucasian ethnic female patients. The study
consisted of a 13-biomarker panel, which were measured in the plasma samples of African
American, Hispanic and Caucasian female patients diagnosed as MCI/mild AD at the Byrd
Alzheimer’s Institute, USF, between the years 2006-2011. Further, we utilized computational
analysis and applied correlation models to identify plasma biomarker levels that correlate with the
early AD status present in each of ethnic groups. These findings provide the necessary data for
designing longitudinal studies where large ethnic groups can be included and the biomarker
selection can differentiate among ethnic groups and disease status. This may open the door to an
individualized medication selection process that will ensure positive drug responses.
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3.2

Materials and Methods
Plasma samples were attained from the USF, Alzheimer Disease Research Center (ADRC)

data base, belonging to African American, Hispanic or Caucasian female patients that have visited
the Byrd Alzheimer’s Institute between years 2006-2011. For a diagnosis of MCI and mild
dementia, both International Statistical Classification of Diseases, 10th Revision, and Diagnostic
and Statistical Manual of Mental Disorders, Revised Third Edition criteria were met [57]. The
study included 50 female minority patients of African American or Hispanic descent and 25 of
Caucasian descent. Of the 75 female patients, 30 samples belong to age-matched female controls
(n=10/group) and 45 samples belong to the female patient population diagnosed with Mild
Alzheimer’s disease (n=15/group). As a measure of neuropsychological performance, participants
were analyzed based on the Florida Cognitive Activities Scale (FCAS). Given the results of the
neurological examinations, diagnostic classification of the patients was determined by the MiniMental State Examination (MMSE) scores (21-30) and the Clinical Dementia Rating (CDR) values
(0-2). A complete clinical history and neuropsychological testing were maintained from the
institute’s ADRC database. All patients have signed a waiver consent form prior to the clinical
visit. Plasma from all control and AD subjects was prepared according to the clinical laboratory
improvement amendments (CLIA) standards, which will make these samples amenable for clinical
trial work. The research protocol for this study was approved by the University of South Florida
IRB committee.
3.2.1

Decision Tree Analysis
We developed decision tree models on the data gathered for each ethnic group in order to

identify homogeneous subgroups embedded in each ethnicity whose members have similar
biomarker levels according to the following models: model #1 (M1) a decision tree on data of
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African American females; model #2 (M2) a decision tree on Caucasian females and model #3
(M3) a tree on Hispanic females. The decision tree method is described in Chapter 2.
3.3

Results
We applied a decision tree learning algorithm, a computational modeling algorithm, to our

data set in order to identify homogeneous subgroups with similar biomarker levels that links them
to the risk of developing AD in each ethnic group. We present three models (Figure 5) for AfricanAmerican, Caucasian and Hispanic women.
The decision tree model learned from the African American female cohort (M1) identified
three biomarkers: Aβ40, Plasminogen activator/inhibitor (PAI.1) and Eotaxin, which can
characterize one homogeneous subgroup, Node 7 and one almost homogeneous subgroup Node 3.
Node 3 with the majority of age-controls is based on the M1_Rule1: (Aβ40 ≤ 126.37 pg/ml and
PAI.1 > 19229 pg/ml) -> Age Control. Further, in this model, Nodes 6,7 identify two mostly to
completely homogenous mild AD groups, which can be characterized following the M1_Rule2:
(Aβ40 > 126.27 and Eotaxin ≤ 103.14) -> Mild AD, M1_Rule3: M1_Rule2: (Aβ40 > 126.27 and
Eotaxin > 103.14) -> Mild AD (Fig. 5a).
Model #2 (M2) was built based on the data set from the Caucasian female cohort and
identified three biomarkers: Cystatin C, Fibrinogen and Plasminogen activator/inhibitor (PAI.1),
which were linked to three subgroups based on the following rules as: M2_Rule1 identifies Node
3 as a homogenous age-matched control group characterized as: (Cystatin C ≤ 1312.95 ng/ml and
Fibrinogen > 2352.15 μg/ml) -> Age Control. M2_Rule2 identifies Node 6 as an almost
homogeneous population of mild AD patient group (n=7/8 subjects) characterized as: (Cystatin C
≤ 1312.95 ng/ml and Fibrinogen ≤ 2352.15 μg/ml and PAI.1 ≤ 22105 pg/ml) -> Mild AD.
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Meanwhile, M2_Rule3 identifies Node 7 as a homogenous mild AD group characterized as:
Cystatin C > 1312.95 ng/ml -> Mild AD (Figure 5 b).
Model #3 (M3) is built on the Hispanic cohort dataset and identified Aβ40 and Cystatin C
as biomarkers linked to one homogeneous subgroup of mild ADs (Figure 5 c). This subgroup
(Node 5) is characterized by M3_Rule1: (Aβ40 > 88.5 pg/ml and Cystatin C > 1076.79 ng/ml) ->
Mild AD. Interestingly, when the Cystatin C rule in this decision tree was applied to the other two
ethnicities, the majority of Caucasians and African American individuals who satisfy this rule were
also Alzheimer’s disease patients. This suggests that Cystatin C is associated with mild AD and
should be studied further as a potential early detector of Alzheimer’s disease.
For each model, the sensitivity and specificity were estimated. Both sensitivity and
specificity of M1 (93% and 70%, respectively) and M2 (87% and 90%, respectively) are
satisfactory; however, M3 has a sensitivity of only 66.7% and was unable to predict a
homogeneous mild AD subgroup albeit this model performed with 100% specificity. Table 3
provides a comparison between predictive powers of the three models after 5 fold cross validation.
There’s a big standard deviation in the predictive performance of the models, which could be due
to the small number in the population the models were built on.
We also developed a decision tree on the whole 75 example dataset, and tried to compare
the variables which showed up in each analysis. Aβ40, Total.Tau and CystatinC were the
biomarkers that appeared in the decision tree on the whole dataset. However, CystatinC appeared
only in M2 and M3; Aβ40 in M1 and M3 and PAI.2 in M1 and M2.
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3.4

Discussion
In this study we analyzed pathological, vascular and inflammatory biomarkers in the

plasma of African American, Caucasian and Hispanic female Mild AD patients and age-matched
control individuals. The goal of this study was to determine effective potential biomarkers that are
specific for each ethnicity and can be used for early detection of Alzheimer’s disease (AD).
Cystatin C is highly relevant to the progression of Alzheimer’s disease [58]. In fact, early
research links cystatin C with amyloid beta found in the vascular walls and senile plaque cores in
the brains of patients with Alzheimer’s disease [59]. The evidence suggests that cystatin C could
even protect the brain against amyloid-induced toxicity by binding to amyloid beta protein and
inhibiting Aβ42 oligomer and fibril formation [59-61]. A study examining an AD patient cohort
consisting of elderly men at the age 77 years found that the reduction of serum cystatin C levels
was significantly associated with the increased risk of Alzheimer’s disease [62].
In our study cystatin C levels were significantly increased in the mild AD female
population compared to the age-matched controls. Further, we report that cystatin C was
significantly higher in Hispanic mild AD female patients compared to the Hispanic age-matched
control group. The computational analysis on the Hispanic cohort dataset identified cystatin C as
a biomarker linked to a homogeneous mild AD subgroup suggesting that cystatin C can play an
important role in the early detection of Alzheimer’s disease.
Interestingly, when this rule (cystatin C>1076.79 ng/ml -> Mild AD) was applied to the
Caucasian and African American cohorts, the majority of subjects that satisfied the rule were mild
AD patients. These results are consistent with studies that associate cystatin C with Alzheimer’s
disease, and suggest cystatin C as a therapeutic biomarker for the early detection of Alzheimer’s
disease [63].
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The decision tree model identified Aβ40 and Eotaxin levels that were significantly
associated with Alzheimer’s disease in the African American female cohort. Hereby, our findings
suggest that plasma Eotaxin levels in the African American female population could be a risk
marker for this ethnic and gender patient cohort, a relationship that has yet to be studied. Such
efforts have been made and in fact, a study measuring chemokine and cytokine levels in a cohort
consisting of 13 controls and 11 Alzheimer’s disease patients reported significant elevation of
serum Eotaxin levels in AD patients compared to the control group; however the study did not
account for differences between ethnic groups in their patient cohort [64].
Despite the non-significant changes measured in the cardiovascular biomarkers levels in
our patient cohort, analysis identified the combination of cystatin C ≤ 1312.95 ng/ml, Fibrinogen
≤ 2352.15 μg/ml and PAI.1 ≤ 22105 pg/ml associated with 87% Caucasian female mild AD
patients. One limitation in applying these analyses is the low number of patients enrolled in this
study; therefore, the models applied here are only suggestive of relevant biomarkers.
Cardiovascular markers have been shown to be modified during Alzheimer’s disease progression
[47,48], for example, Jaeho Oh et al. [58] reported increased levels of plasma PAI-1 levels in MCI
and AD subjects as compared to normal controls. The authors also reported that the PAI-1 levels
were gradually increased as the dementia progressed [59]. In addition, Genome Wide Association
Studies (GWAS) confirmed the APOE e4 allele as a risk factor and identified ABC7, a membrane
transporter protein, to be a strong genetic risk factor of AD in African American cohort [65]. Both
genes are involved in cholesterol transport, and given that cholesterol metabolism involvement in
vascular conditions and its implication in Alzheimer’s disease [66] it presents a potential marker
for future studies.
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When comparing the decision tree on the total population of the 75 subjects (Figure 6) and
trees on each ethnic group, we can see that Cystatin C is an identifying biomarker for Caucasians
and Hispanics, but not for African Americans. Fibrinogen was a biomarker for Caucasians, and
not for the other ethnicities. And Aβ40 which was the main identifying biomarker for the whole
dataset, does not seem to be an important one for Caucasian women.
One limitation in applying these analyses is the small sample size enrolled in this study;
therefore, the models applied here are only suggestive of relevant biomarkers. To our knowledge,
very few studies have analyzed the relation of ethnicity to AD in such an inclusive panel of
biomarkers. Considering that clinical manifestations are often the result of complex extrinsic social
factors, there is growing awareness that these factors may influence some of the disparities in
clinical presentation and treatment [61,62]. We believe that finding biomarkers that link biological
risk factors to cognitive function and determining biomarker disparity among ethnic groups can
significantly advance research for the development of effective preventive therapeutic
interventions in the treatment of Alzheimer’s disease.
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Table 3 Prediction power of the three models after 5-fold cross validation
Model

Sens (s.d.)

Specs (s.d.)

0.66 (0.23)

0.57 (0.23)

0.96 (0.06)

0.54 (0.22)

African Americans

0.61 (0.16)

Hispanics

0.67 (0.23)

Caucasians

Whole data

0.7 (0.14)

0.6 (0.14)

0.6 (0.14)

0.64 (0.17)

1

CystatinC

(a)

0.2
0

M3- Hispanics

Node 3 (n=6) 1

Mild AD

1

> 22105 (pg/ml)

0.4

Sensitivity: 0.66
Specificity: 1.00

Aβ40
≤ 88.45 (pg/ml)

> 88.45 (pg/ml)

0.8
0.6
0.4
0.2
0

Node 5 (n=5) 1

0.8
0.6
0.4
0.2
0

≤ 22105 (pg/ml)

Node 6 (n=8) 1

0.8
0.2

(b)

3

CystatinC

0.4
0.2
0

Node 4 (n=8) 1

(c)

0.8
0.6
0.4
0.2
0

Node 5 (n=10) 1

Age Control

0.6

> 1076.79 (ng/ml)

0.8

Mild AD

0.8

Age Control

Node 2 (n=7) 1

Mild AD

Mild AD

Age Control

≤ 1076.79 (ng/ml)

0.2

0.6
0.4
0

Figure 5 Decision tree models for each ethnic group.
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Node 7 (n=6) 1

Age Control

0

4

PAI.1

0.6
0.4
0

Mild AD

Mild AD

0.2

0.6

Age Control

0.4

0.8

Mild AD

0.6

0.4
0

Age Control

0.2

0.8

0.6

> 2352.15 (μg/ml)

Node 7 (n=7) 1

Mild AD

0.8

> 1312.95 (ng/ml)

Sensitivity: 0.87
Specificity: 0.90

≤ 2352.15 (μg/ml)

> 103.14

Node 6 (n=5) 1

Age Control

Age Control

0

≤ 103.14

Mild AD

Age Control
Mild AD

0.2

0.4

Fibrinogen

Age Control

> 19229 (pg/ml) ≤19229 (pg/ml)

0.6

2

5

Eotaxin

PAI.1

0.8

≤ 1312.95 (ng/ml)

Age Control

> 126.27 (pg/ml)

Mild AD

≤ 126.27 (pg/ml)

Node 4 (n=5) 1

0.8 (0.1)

1

Aβ40

2

Node 3 (n=8) 1

0.6 (0.25)

M2- Caucasian

M1- African Americans
Sensitivity: 0.93
Specificity: 0.70

Acc (s.d.)

0.8
0.6
0.4
0.2
0

1

Aβ40
≤ 136.69 (pg/ml)

>136.69 (pg/ml)

5

CystatinC

2

Total.Tau

> 103.14

0.4
0

0.4
0.2
0

Age Control

0.6

Node 9 (n=17) 1

0.8
0.6
0.4
0.2
0

Mild AD

0.8

0.6

Node 8 (n=11) 1

Age Control

0.2

≤ 1780

Mild AD

0

0.8

Node 7 (n=10) 1

Age Control

0.4

Node 4 (n=19) 1

> 1780

Mild AD

0.2

0.6

≤0.06 (pg/ml)
Age Control

Age Control

0.8

Mild AD

Node 3 (n=18) 1

≤ 103.14

Fibrinogen

Mild AD

> 0.06 (pg/ml)

6

Figure 6 Decision tree on the whole 75 subjects of the study.
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0.8
0.6
0.4
0.2
0

CHAPTER 4: A COMPARISON OF RULE-BASED ANALYSIS AND REGRESSION
METHODS IN UNDERSTANDING THE RISK FACTORS FOR STUDY
WITHDRAWAL IN A PEDIATRIC STUDY
4.1

Introduction
Understanding the factors associated with the risk of individuals withdrawing from a study

is an important first step towards identifying the eventual health needs of different individuals
within a population [67]. This lays the foundation to develop and deliver appropriate resources to
the right targets, called “tailored health interventions”. Evidence suggests that individuals respond
better to tailored care than standardized care that is designated for the average population [68-71].
Therefore, health professionals need to identify the subgroups of individuals characterized by
different patterns of risk factors. However, rather than identifying subgroups, traditional
intervention studies often focus on the outcome of interest for the population as a whole [67,72,73].
One commonly adopted approach is to use logistic regression to identify factors associated with
study withdrawal [74-76]. However, this approach only models the average effects of the risk
factors. Consequently, it is likely that the interventions developed from regression models will be
geared toward the average member of the population, with less consideration of the special needs
of different subgroups [77].
The aim of our study was to illustrate the use of the rule-based analysis [78-80] as an
exploratory technique in an epidemiologic context. The rule-based analysis [78-80] is particularly
useful for identifying the subgroups embedded in a dataset - whose members share similar risk
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patterns - that influence the outcome of interest. A rule describes the range of values for one or
more risk factors that are associated with either an increase or decrease in risk for withdrawal in a
subset of individuals. Thus, rules provide a way to define the risk pattern of subsets of individuals
where each rule may indicate a specific unmet health need or warning signal for study withdrawal.
By identifying the rules from observational studies, a comprehensive set of risk-predictive rules
can be considered as a set of sensors, providing us personalized risk estimation by looking into the
risk patterns for each individual.
Specifically, we used a recently developed rule-discovery algorithm for the rule-based
analysis, the RuleFit method [80], which is one example from a huge array of rule-based methods
that are promising for epidemiologic research. The RuleFit method has an advantage over logistic
regression because it relies on a nonparametric model with fewer modeling assumptions, random
forests [79]. RuleFit creates rules from a random forest which is capable of identifying the risk
predictive rules. Also, the rule-based analysis permits an individual’s risk to be predicted on the
basis of only one, or at most a few, risk factors, whereas scores derived from regression models
require that all covariates be available.
We demonstrate rule-based analysis using data from a large multinational epidemiological
natural history study of type 1 diabetes mellitus (T1DM), the Environmental Determinants of
Diabetes in the Young (TEDDY) study [81]. Specifically, we used the rule-based analysis for
predicting study withdrawal during the first year of the TEDDY study, by effectively integrating
the psychosocial, demographic, and behavioral risk factors collected at study inception. We
compare the rule-based analysis with a previous analysis that was conducted on the same data [76].
The previous analysis used traditional logistic regression methods to identify features, called
factors, collected at study inception that were strongly associated with study withdrawal during
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the first year of TEDDY [76]. However, the way these factors interact with each other and the way
these interactions might define subgroups in the study population with different risk levels remains
unknown. Therefore, we tested the hypothesis that the rule-based analysis can identify riskpredictive rules useful for stratifying the study population into different subgroups with different
risk levels for study withdrawal in the first year of TEDDY. The previous analysis [76] provided
us an opportunity to critically evaluate the potential added value of a rule-based analysis over and
above that provided by traditional logistic regression methods. Also, we considered how the rulebased method could lead to more informed intervention strategies or prioritization of the
intervention allocation to the study participants. An example of intervention allocation could be
assigning a nurse to the participants who are at higher risk of withdrawal from the study to follow
up for each appointment. By conducting this comparison, we also hoped to identify some practical
guidelines for when should we use rule-based methods and when a regression model would be
more preferable, enriching the analytic toolbox of today’s epidemiologists to address emerging
data challenges.
4.2

Materials and Methods

4.2.1 The TEDDY Study
TEDDY is a natural history study that seeks to identify the environmental triggers of
autoimmunity and T1DM onset in genetically at-risk children identified at three centers in the
United States (Colorado, Washington, and Georgia/Florida) and three centers in Europe (Finland,
Germany, and Sweden). Infants from the general population with no immediate family history of
T1DM, as well as infants who have a first degree relative with T1DM, are screened for genetic
risk at birth using human leukocyte antigen genotyping. Parents with infants at increased genetic
risk for T1DM are invited to participate in TEDDY. Parents are fully informed of the child’s
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increased genetic risk and the protocol requirements of the TEDDY study, including the
requirement that eligible infants must join TEDDY before the infant is 4.5 months of age. The
TEDDY protocol is demanding with study visits for blood draws and other data and sample
collection scheduled every three months during the first four years of the child’s life and biannually
thereafter. Parents are also asked to keep detailed records of the child’s diet, illnesses, life stresses
and other environmental exposures. TEDDY obtains written consent from the parents shortly after
child’s birth for obtaining genetic and other samples from the infant and also parents. Details on
study design and methods have been previously published [81]. The study methods were carried
out in accordance with the approved guidelines by local Institutional Review or Ethics Boards and
monitored by an External Evaluation Committee formed by the National Institutes of Health.
4.2.2

Study Sample
This analysis focused on two groups of families from the general population used in the

previous logistic regression study [76] : 2,994 families who had been active in TEDDY for ≥ 1
year and 763 families who withdrew from TEDDY during the first year. Both the prior and current
analyses were limited to general population families because study withdrawal among the first
degree relatives population was rare.
4.2.3

Study Variables
Study variables were selected from data collected on the screening form at the time of the

child’s birth and from interview and questionnaire data collected at the baby’s first TEDDY visit.
These variables included: demographic characteristics---TEDDY country (Finland, Germany,
Sweden, United States); mother’s age (in years); child’s gender; maternal health during pregnancy--number of illnesses, gestational diabetes or type 2 diabetes (yes/no); mother’s lifestyle behaviors
during pregnancy---smoked at any time during pregnancy (yes/no), alcohol consumption (no
34

alcohol, 1-2 times per month, ≥ 3 times per month during each trimester), employment status
(worked during all 3 trimesters/did not work at all or reduced work hours); baby’s health status--birth complications (yes/no), health problems since birth (yes/no), hospitalizations after birth
(yes/no); number of stressful life events during and after pregnancy; mother’s emotional status
including worry and sadness during pregnancy (rated on 5 point scales), anxiety about the child’s
risk of developing diabetes measured by a six-item scale adapted from the State component of the
State-Trait Anxiety Inventory [68-70]; the accuracy of the mother’s perception of the child’s risk
for developing diabetes (accurate: indicating the child’s T1DM risk was higher or much higher
than other children’s T1DM risk; inaccurate: indicating the child’s T1DM risk was the same,
somewhat lower or much lower than other children’s T1DM risk); and whether the child’s father
completed the initial study questionnaire (yes/no). The study variables are listed in Table 4.
4.2.4

Previous Logistic Regression Results
Multiple logistic regression was used to identify significant predictors of early withdrawal

from TEDDY. Variables were entered in blocks in the following order: demographic variables
(country of residence, child’s gender, mother’s age); pregnancy/birth variables (maternal diabetes,
illness in mother or child, birth complications, maternal smoking; maternal drinking; maternal
employment outside the home, maternal worry or sadness during pregnancy, number of stressful
life events occurring during pregnancy or after the child’s birth); father’s participation in TEDDY
defined by father’s completion of a brief questionnaire; and mother’s reactions to the baby’s
increased T1DM risk (anxiety and accuracy of mother’s perception of the child’s T1DM risk).
Nine percent of the study sample (N=326) had missing data on one or more variables. The
withdrawal rate for participants with complete data (19%) was substantially lower than the
withdrawal rate among those with some missing data (35%). Consequently, the analysis was first
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completed for those with no missing data and then rerun for the full sample using multiple
imputation to generate appropriate parameter estimates for missing data using the Proc MI and
Proc MIANALYZE procedures available from SAS 9.1 [71]. Table 5 provides the results of the
final logistic regression model for the sample of 3,431 TEDDY participants with no missing data.
The model was highly significant (Chi-Square = 264.87 (12), p <.0001) and accurately placed
81.6% of the sample into their respective group (Actives versus Withdrawals). The data in Table
5 also provides the final logistic regression model for the total sample, with multiple imputation
methods used to replace missing data. Because the early withdrawal rate was higher among
participants with missing data, we added a variable to the imputed model, >1 missing data point
(yes/no). The presence of >1 missing data points predicted early drop-out over and above all other
variables in the model. The descriptive information for each of the significant predictors is
provided in Table 6.
4.2.5

Statistical Methods
Basic Idea of the RuleFit Method. We used RuleFit [80] to discover the hidden rules that

may be predictive of the risk of early withdrawal in subsets of TEDDY individuals. A rule consists
of several interacting risk factors and their ranges. We are interested in the rules by which the
subjects can be stratified by distinct risk levels. For example, a rule consisting of State Anxiety
Inventory Score > 45 and Dad Participation = NO would be useful if the subjects who can be
characterized by this rule have a higher risk of early withdrawal. RuleFit is a computational
algorithm that can scale up for high-dimensional applications (e.g., with a large number of
variables) for rule discovery, and is capable of exhaustively searching for potential rules on a large
number of candidate risk factors. It has two phases, the “rule generation phase” and “rule pruning
phase.”
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4.2.5.1

Rule Generation
At this stage, random forests [79] is used to exhaustively search for candidate rules over

the potential risk factors. Random forests is a high-dimensional rule discovery approach that
extends traditional decision tree models [12]. Specifically, a random forest generates a number of
trees, with each tree being generated from a subpopulation generated by bootstrapping the original
dataset. Since we can extract rules from trees in a forest and each rule could characterize a
subpopulation, the random forest is actually a collection of rules that are trying to characterize the
whole dataset.
4.2.5.2

Rule Pruning
As a heuristic search approach, random forests may produce a large number of rules that

can be redundant or irrelevant to predicting early withdrawal due to overfitting. To address this,
the sparse regression model [82,83] can be applied to select a minimum set of risk-predictive rules,
by using all the potential rules as predictors and the withdrawal status as the outcome. The sparse
regression model is a high-dimensional variable selection model that can be applied on a large
number of variables, and has been widely used in bioinformatics and systems biology [60,84].
Unlike other rule pruning methods, which remove antecedents with little predictive power, LASSO
ejects the whole redundant rule out of the tree. That is the path from the root to the leaf, which
makes up the rule.
In what follows, we illustrate the details of how the RuleFit method uses the three models,
a decision tree, random forests, and sparse linear regression models, in the rule generation stage
and the rule pruning stage:
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4.2.5.3

Stage 1 of RuleFit - Rule Generation
Rule generation is computationally challenging, since the number of potential rules grows

exponentially in relationship to the number of risk factors, e.g., even for 100 variables, let the
maximum number of variables in a rule be 3, and 4 possible cutoff values for each variable, then
the potential number of rules is ~107. Given such a large number of potential rules, an intelligent
rule generator is needed to narrow down the search by effectively detecting high-quality riskpredictive rules. Decision trees with rule generation from them provide such an intelligent rule
generator. We can extract rules from a decision tree by which we can segment the population into
different subgroups. For example, we used a decision tree model for analyzing the TEDDY dataset
to divide the population into subgroups based on the percentage of study withdrawals in each
subgroup. The decision tree model is a nonparametric method that automatically explores the given
risk markers for a tree that has high accuracy in predicting study withdrawal. In our analysis, we
built a decision tree on all the data as shown in Figure 7, three subgroups with distinct risk levels
were identified and could be characterized by rules defined by maternal age, smoking status,
number of missing data, and a geographical indicator for Finland. For example, the leftmost node
characterizes a subgroup of subjects, in which all of them have Maternal age < 27.5 and Finland =
NO. The risk of study withdrawal in this subgroup is 0.38. This analysis demonstrated that the
decision tree model is a powerful tool for detecting the subgroups that can be characterized by
rules. Note that, the cut-off value of each marker used in Figure 7 was automatically determined
by the Recursive Partitioning Algorithm (RPA) [12].
One limitation of the decision tree is that only exclusive rules can be identified. For
instance, the decision tree in Fig.1 implies that each participant can only be characterized by one
single rule, which doesn’t consider the possibility that a participant may have multiple risk patterns
38

characterized by different factors or different interactions between factors. As a remedy, random
forests [79] generates a number of trees: in each iteration, we build a decision tree on a
bootstrapped sample of the training set randomly choosing a test feature from a specified number
of top ranked features or “risk factors”, and this process iterates until the pre-specified number of
trees are created [79].
To understand a random forest, it is worth mentioning that the essence of this iterative
procedure is to generate a large number of substantially different trees, since the more similar the
trees are, the less advantage building multiple trees has. In order to achieve this goal,
randomization methods are used, which is the reason for the name “random forests”. Each tree is
built on a bootstrapped training set using a subset of risk factors (features), the heterogeneity of
the subjects is well addressed in the random forest model, increasing the likelihood of detecting
meaningful risk-predictive rules for different subgroups [80]. As each tree can be decomposed into
a number of rules, e.g., in Figure 7, we could extract at least five rules where each rule corresponds
to a path to a leaf node in the tree, with random forests we can collect many rules.
4.2.5.4

Stage 2 of RuleFit - Rule Pruning
While in most machine learning methods, rule pruning is about deleting antecedents from

rules, in RuleFit the whole rule is ejected from the tree. Here, rule pruning is essentially a procedure
of selecting a subset of rules out of a pool of

candidate rules, denoted as

=

,

,…,

,

which are predictive of the output variable . This problem is particularly challenging in highdimensional settings where we have a large number of generated rules so that

is large. One

solution to select the most critical rules is to adopt the Least Absolute Shrinkage Selection Operator
(LASSO) [82], which is a sparse linear regression model that is capable of identifying a subset of
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relevant variables out of a huge list of candidate variables. Specifically, the formulation of LASSO
is
min‖Y − R ‖ + ‖ ‖ .

(4-1)

Here, R is a binary variable standing for each rule, 1 if the rule is fulfilled and 0 otherwise

and the square error term, ‖Y − R ‖ is used to measure the model fit. The L1-norm penalty term
‖ ‖ , is defined as the sum of the absolute values of all elements. The user-specified penalty

parameter, , aims to achieve an optimal balance between the model fitness and model complexity
– a larger

will result in a sparser estimate for . It has been shown that LASSO is efficient on

variable selection both from theoretical research [82] and empirical studies [60,83-85]. Efficient
algorithms have been developed to solve the optimization problem, such as the shooting algorithm
[82], proximal gradient algorithms [83], etc. Through LASSO, we expect that the rules with critical
risk factor patterns will be identified with controlled redundancy. In our study, since the output
variable , i.e., the withdrawal status, is a binary variable, sparse logistic regression [83] is a better
choice than linear regression, which can be readily applied in the R package of RuleFit [80].
In summary, RuleFit is computationally efficient since efficient algorithms have been
developed for both Random Forests and sparse linear regression models. RuleFit has an automated
cross-validation procedure for tuning its parameters, such as the number of trees, the size of the
trees and the penalty parameter

in LASSO, which can be used to obtain a set of high-quality

rules. More details about RuleFit can be found in [80]. Figure 8 also provides a schematic
description of the Rulefit algorithm.
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4.3
4.3.1

Results
Identified Risk-Predictive Rules
Table 7 provides the risk-predictive rules identified by the RuleFit algorithm for the Active

and Withdrawn families used in the previous logistic regression analysis [76]. We generated 2000
rules with average number of 4 terminal nodes, which resulted in generating 300~350 trees and
picked the 8 top rules selected by the algorithm. Changing the parameter max-rules (the total
number of rules generated) and also different seeds resulted in a different rule set; however, the
top rules stayed the same. The risk factors identified in the risk-predictive rules are the same as
those identified in the previous logistic regression analysis: demographic factors including
maternal age and country, maternal lifestyle factors during pregnancy including as smoking,
drinking, and working outside the home, psychosocial factors including the mother’s perception
of the child’s risk and her anxiety about the child’s risk, dad participation, and the number of
missing data points. In addition, the interaction between the state anxiety inventory score with the
risk perception accuracy found in the previous study, which was further validated in the rule-based
analysis (see Table 5 and Table 6). However, the rule-based analysis was more powerful at
detecting the interactions between the risk factors, by including two or more variables and their
ranges in a single rule. In addition, the rule-based approach identified the number of negative life
events as a risk factor, a variable that was not significant in the prior logistic regression analysis.
And the rule-based approach found no significant role for child gender, which had a weak effect
in the prior analysis (see Table 5). Note that the rules shown in Table 7 were identified by LASSO
from 2000 candidate rules generated by random forests.
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4.3.2

Investigation of the Risk Levels of Withdrawal When Matching Risk Patterns
We next investigated the risk level of matching each of the rules by computing the study

withdrawal rate for each subgroup that matched a rule. Figure 9 illustrates the withdrawal rates of
each of the eight identified rules as well as the overall withdrawal rate of the whole study
population. The number of subjects in each subgroup is also shown in Figure 9. It is clear that
matching any of the first four rules will boost the risk of early withdrawal dramatically, while
endorsing any of the latter four rules will help decrease the risk significantly. Approximately 10
percent of the study population matched no rules and their withdrawal rates were relatively high,
suggesting that there may be other important subgroups that were not detectable with the available
measures.
4.3.3

Investigation of the Redundancy of the Rules
One important technical issue in rule-based analysis is the control of redundancy of rules.

Two rules are redundant if a participant matches one rule and this participant will match the other
rule. Obviously, it is less desirable to have two rules that largely overlap with each other. We
investigated the redundancy of the 8 rules and present the results in Figure 10. Figure 10 can be
read in this way: the pie graph on row (corresponds to rule ) and column (corresponds to rule
) records the proportion of the participants matching rule i who also match rule j. It can be seen
that, there is some overlap between some rules, such as rule 1 and rule 4, rule 5 and rule 7. The
reason for a correlation between two rules may be that both rules share some common risk factors,
e.g., both rule 1 and rule 4 involve maternal age < 27.5 in their definitions.
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4.4

Discussion
In this dissertation, rule-based analysis [80] has been proposed to enrich the toolbox of

epidemiological intervention studies that have been relying on regression models. We used data
from the TEDDY study and demonstrated that the rule-based analysis can effectively identify riskpredictive rules from the psychosocial, demographic, and behavioral risk factors. The 8 identified
rules by RuleFit are found predictive of early withdrawal during the first year of the TEDDY study.
The 8 rules involve different sets of risk factors, highlighting the different nature of the withdrawal
risk for each of these subgroups. Note that these 8 rules are not exclusive, giving the flexibility
that an individual can show multiple risk patterns simultaneously.
We also compared the rule-based analysis with the previous analysis that was conducted
on the same data [76]. We found that both methods detected almost the same set of risk factors,
providing validation of our rule-based analysis. Note that the previous analysis only identified the
average effects of these risk factors across the whole population, without considering how these
risk factors interact with each other in determining the risk of early withdrawal. The rule-based
analysis was superior at detecting interactions between the risk factors in each rule.
As each rule characterizes a distinct risk pattern that consists of different risk factors, a
further investigation of the particular characteristics of each rule may help identify the special
health needs of the subgroup whose members match this rule, leading to tailored interventions. For
example, as revealed in Rule 3, for mothers who are highly anxious about their child’s T1D risk
with a state anxiety inventory score > 45, the lack of participation of the father increases the risk
of study withdrawal. In an effort to tailor an intervention to this specific subgroup, a study nurse
might be assigned to the family having this risk pattern to enhance the psychological support for
the mother and encourage the participation of the father. On the other hand, the rules are also
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helpful for developing general-purpose interventions. For instance, as smoking during pregnancy
was selected in multiple rules, investigations may be conducted to understand why this behavior
is related to the risk of study withdrawal. If smoking during pregnancy was found to be an indicator
of less health-conscious attitudes, a tailored intervention might be developed for mothers who
smoked during pregnancy to increase their health consciousness in an effort to reduce their risk of
study withdrawal. As tailored interventions are developed and deployed, it is also important to
evaluate the efficacy of these interventions for the subgroups separately, in order to identify the
best intervention strategy for each subgroup.
The rule-based analysis also identified negative life events as a risk factor for early
withdrawal, which was not detected by the logistic regression model used in the previous study
[76]. Previous studies have linked negative life events with immune system functioning [86,87]
and the onset of T1DM [88,89]. While the mechanism underlying the linkage between the negative
life events and study withdrawal remains unknown, it is reasonable to expect that mothers
experiencing numerous negative life stresses may not have the personal resources to remain in the
study. Certainly tailoring an intervention to this subgroup of individuals seems warranted.
The rule-based method has a number of advantages when handling complex datasets. It
can be used with a mix of nominal, ordinal, integer or continuous variables and it can combine a
mixture of variables –-demographic, biological, psychological---without interpretation difficulty.
Also, as rules are scale independent, data does not need to be standardized. Finally, the rules will
permit some individuals to be classified on the basis of only one, or at most a few, risk factors,
whereas risk scores derived from regression models require that all the risk factors are available.
There are limitations of the rule-based approach for epidemiologic studies. First, it is not
suitable for studying the overall impact of a single independent variable on the outcome variable.
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This is because a single independent variable may play a role in multiple rules, which results in
difficulty investigating its overall effect on the whole population. Also, domain insight is very
important in the identification of the rules using RuleFit. Due to the automatic nature of the rulebased approach, it is tempting to simply enter all possible candidate variables into the program
without justification of which independent variables should be considered. It has been
recommended in the literature [90] that prior knowledge regarding the relationship between the
independent and dependent variables should be incorporated with the rule-based models. One of
the reasons the rule-based approach yielded remarkably similar findings to the logistic regression
approach in terms of identifying risk factors per se, is that considerable thought was put into
variable selection and measurement by the TEDDY group. Rule-based models should not be used
for blind exploration of large data sets and should benefit from careful a priori variable selection.
In general, through the study of the rule-based method in the TEDDY cohort and
comparison with a previous study that used logistic regression methods, we could draw the
following practical guidance for how to integrate rule-based analysis methods into the existing
epidemiological toolbox. If there is a strong hypothesis that multiple subgroups may exist in the
dataset, the rule-based method could be a very useful approach. On the other hand, subgroups may
vary from dataset to dataset, and the rules (and the risk factors involved in these subgroups)
identified by the rule-based method may vary from dataset to dataset as well. It is important to
understand that the rule-based method is a customized method that is tailored for analyzing an
individual dataset, so whether or not the results identified from one dataset could be generalized
to another dataset depends on the subgroup structure of the new dataset. While flexibility of an
analytic method usually comes with the risk of overfitting, a customized method also needs
customized expertise or solid domain knowledge of the dataset. Finally, rule-based methods can
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be considered as opportunistic methods that aim to discover sub-groups, but the results identified
by rule-based methods are not necessary exclusive. For example, it is possible that there are more
rules besides the eight rules identified from the TEDDY cohort by the RuleFit.
In summary, we believe that the rule-based approach will be useful in many epidemiologic
studies, particularly with heterogeneous populations consisting of subgroups of individuals. The
distinct risk factors that define each subgroup could also reflect a different mechanism of
withdrawing from the study, leading to development of different intervention strategies. Besides
the utility in designing tailored interventions, it can also help with the prioritization of the
intervention targets, e.g., we could choose to eliminate a particularly high-risk subgroup at the
beginning of a clinical study. Note that the RuleFit algorithm introduced here is one example from
a huge array of the rule-based methods that are promising for epidemiologic research in general.
How to properly adopt them for addressing the analytic challenges in epidemiologic studies will
be an important future research topic.
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Table 4 Study variables of the model
Country
Child’s Gender
Maternal Age

Maternal Health During
Pregnancy

United States
Finland
Germany
Sweden

Number of illnesses
Gestational Diabetes/ Type2 Diabetes

Smoking (Yes/No)
Alcohol Consumption
Maternal Lifestyle during
Employment during pregnancy
pregnancy
Baby’s health status/ birth complications
(Yes/No)
Health problems since birth (Yes/No)
Mother’s Emotional status during pregnancy
including sadness or worry (Yes/No)
Mother’s Perception of the Child’s risk of Developing Type I Diabetes
State Anxiety Inventory Score
Dad participation
Missing Data points
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Table 5 Logistic regression results [76]
Predictor
variable
Intercept

Country

Sample with No Missing Data (N=3431)
Estimate

0.424

Finland

-0.420

0.130

0.001

Sweden

-0.342

0.110

0.002

United States
Germany

0.278

0.160
-0.058

0.222

ref

0.092
0.009

Maternal Lifestyle Behaviors during Pregnancy
Smoked

No

Yes

None

0.841

Alcohol
consumption 1-2
-0.343
in last
times/month
trimester
>2 times/month -0.424
Worked all
trimesters

Dad
participation
Risk
perception

P-value

1.126

No
Yes
Maternal age (years)

Child sex
female

SE

No

0.117

0.008

ref

0.211

OR

95% Confidence
Interval

Sample with missing data
imputed (N=3757)
β

SE

0.982

0.400
ref

P-value
0.014

0.657

0.509

0.848

-0.431

0.123

0.0004

0.711

0.572

0.882

-0.346

0.104

0.002

2.915
0.961

0.217
-0.053

0.086 0.012
0.009 <0.0001

1.321

0.081 2.316
<0.0001 0.944
ref

<0.0001 2.318

0.854

1.840
0.927

2.042

0.154

0.218

0.481

ref

1.841

2.918

0.803

0.117 <0.0001

0.709

0.531

0.948

-0.280

0.140

0.045

0.654

0.350

1.222

-0.401

0.299

0.180

<0.0001 0.673

0.559

0.811

-0.364

0.090 <0.0001

ref

0.148

0.020

0.319

0.183

ref

ref

Yes

-0.396

0.095

Yes

-0.569

0.162

0.0005

0.566

0.412

0.778

-0.608

0.146 <0.0001

Accurate

-1.257

0.375

0.0008

0.284

0.137

0.593

-1.032

0.354

0.009

0.011

1.041

0.018

No

Underestimate

State Anxiety Inventory score

State Anxiety Inventory score
x risk perception
>1 missing data points

0.001

0.023

0.006

ref
ref

0.835
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1.001

1.023

0.989

1.005

1.014

ref

ref

0.004

0.001

0.006

0.825

1.321

0.464

0.007

0.009

0.039

Table 6 Characteristics of TEDDY actives and withdrawals [76]
Characteristic
Country
Finland
Germany
Sweden
United States
Child sex
Male
Female

Maternal age (years)

Actives
(n = 2994)
N (%)
747(84%)
106(75%)
1052(82%)
1089(75%)
N (%)
1538 (81%)
1456 (78%)

M (SD)
30.8 (5.0)
Maternal Lifestyle Behaviors During Pregnancy
Smoking
N (%)
Smoked
296(63%)
Did not smoke
2602(84%)
Data missing
96(54%)
Alcohol consumption at 3rd
N (%)
trimester
Alcohol 1-2 times per month
474(87%)
Alcohol ≥ 3 time per month
105(89%)
No alcohol
2359(79%)
Data missing
56(45%)
Employment status
N (%)
Worked all 3 trimesters
1418(85%)
Reduced work, quit, or did
1426(77%)
not work at all
Data missing
150(61%)
Dad Participation in TEDDY
N (%)
Participated
2813(82%)
Did Not Participate
181(57%)
Maternal Reactions to Child’s Increased TIDM Risk
Risk perception
N (%)
Accurate
1809(84%)
Underestimate
1132(77%)
Data missing
53(45%)
State Anxiety Inventory score
M (SD)
Total Sample
38.7(9.7)
Risk Perception: Accurate
38.8(10.2)
Risk Perception:
38.4(10.2)
Underestimate
N (%)
Data missing
46 (42%)
Missing Data
N (%)
≤1 missing data points
2944 (81%)
> 1 missing data points
50 (42%)
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Withdrawals
(n =763 )
N (%)
140(16%)
36(25%)
231(18%)
356(25%)
N (%)
352 (19%)
411 (22%)

Total Sample
(n = 3757)
N
887
142
1283
1445
N
1890
1867

N (%)
171(37%)
510(16%)
82(46%)
N (%)

N
467
3112
178
N

72(13%)
13(11%)
609(21%)
69(55%)
N (%)
251(15%)
417(23%)

546
118
2968
125
N
1669
1843

95(39%)
N (%)
624(18%)
139(43%)

245
N
3437
320

N (%)
355(16%)
343(23%)
65(55%)
M (SD)
40.8(10.6)
41.7(10.4)
39.9(10.8)

N
2164
1475
118
M (SD)
39.1(9.9)
39.3(9.6)
38.8(10.4)

N (%)
63 (58%)
N (%)
695 (19%)
68 (58%)

N
109
N
3639
118

M (SD)
28.5 (5.7)

M (SD)
30.4(5.2)

Table 7 The 8 rules identified by the RuleFit method.
Rule 1 (risk increasing rule)
Maternal age < 27.5
Finland = NO

Rule 3 (risk increasing rule)
State anxiety inventory score > 45
Dad participation = NO
Rule 5 (risk decreasing rule)

Worked all trimesters = YES
Smoker during pregnancy= NO

Rule 7 (risk decreasing rule)
Smoker during pregnancy = NO
State anxiety inventory score < 45
Number of missing data points ≤ 1

Rule 2 (risk increasing rule)
Smoker during pregnancy = YES
Accurate risk perception = NO
State anxiety inventory score > 45
Rule 4 (risk increasing rule)
Maternal age < 27.5
Accurate risk perception = NO
Alcohol consumption in last trimester < 2
times per month
Rule 6 (risk decreasing rule)
Finland = NO
Alcohol consumption in last trimester >0
Number of negative events < 2
Rule 8 (risk decreasing rule)
Maternal age > 27.5
Smoker during pregnancy = NO
Number of missing data points ≤ 1

Figure 7 A decision tree learned from the TEDDY data.
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Figure 8 Flow diagram of the RuleFit algorithm.
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Figure 9 Proportion of early withdrawal of the eight rules and the overall population.

Figure 10 Investigation of the redundancy of the 8 rules.
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CHAPTER 5: HIGH-THROUGHPUT SCREENING FOR RULE DISCOVERY FROM
ADRC (ALZHEIMER’S DISEASE RESEARCH CENTERS) DATASETS

5.1 Introduction

Alzheimer’s disease (AD) is the most common form of dementia for which there has not

been any disease modifying therapy so far. It is expected that by 2050 there could be 100 million
people worldwide suffering from AD. However, if the disease is detected at its initial stages, there
would be a chance to delay the progression of the disease. Considering the cognitive decline in the
patient and its consequences on the quality of life of the patients and her/his family, selecting
biomarkers that could help in detecting the disease at its early stages is of high importance.
Complex diseases such as Alzheimer’s are influenced by a combination of genetic and
environmental risk factors and their interactions. Neuropsychological evaluations are the very
initial stage of differentiating normal subjects from the ones who are prone to progression to AD.
Several studies have shown a correlation between Neuropsychological tests and biomarkers that
can detect the progression process to dementia. [4,91,92]
In this study we use a dataset from the Alzheimer’s disease Research Center (ADRC) in
Tampa, Florida. The ADRCs provide information and referral services to adults with mental
illnesses and assign a degree of urgency to clients who require assistance. They also manage the
availability of financial resources for certain key long-term care programs targeted for elders to
ensure financial viability and stability. The dataset consists of the results of neurological
examinations, medical information, family history and a battery of neuropsychological tests.
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The

battery

of

neuropsychological

tests

of

ADRC

includes

16

different

Neuropsychological tests, which contain 290 different variables. Since administrating so many
tests would take significant time and some of these tests would measure the same information, we
are trying to find redundant tests in this battery of tests and see how we could come to the same
conclusion about the pathological group of a subject by using a subset of the neuropsychological
tests instead of administering all of them.
Previous methods available for dimensionality reduction and high-dimensional data
analysis mainly focus on personalized feature selection and rarely pay attention to interaction
between the variables. Our challenge is to reduce the number of variables, and identify highly
synergistic groups of variables, then discover rules from a high-dimensional dataset considering
not only the variables themselves, but also their interactions and ranges. We use statistical models
to select rules and minimize uncertainty.

5.2 Data and Methods
5.2.1 Data

The data set of this study comes from ADRC at Byrd Alzheimer’s institute. The original

dataset consisted of 353 variables including demographic information, Neurological examinations,
medical history and a battery of psychological tests. A set of 25 summarizing variables were
selected by the Byrd Alzheimer’s institute and we limited our analysis to them. These variables
included age, gender, number of years of schooling in U.S., Mini Mental State Examination
(MMSE), Digit Span (Forward and Backward score), Hopkins Verbal Learning test (total trial 13, delayed recall, Recognition true positives), Trail Making (A, B), Digit Symbol ss, Block Design
ss, Category Fluency Total, Verbal Fluency total, Sit Retrieval (Total trials 1–3, The
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neuropsychological test Bag with a 20 min delay, Recognition recall total), Judgment of Line
Orientation, Mohs Time, Visual Reproduction (immediate total score, delayed total score), Boston
Naming test, spontaneous (total), similarities (WAIS) ss, Wide Range Achievement Test – 3rd
edition.
Based on the results of all the neuropsychological tests the subjects are categorized into
three groups of Normal Controls (NC), Mild Cognitive Impairments (MCI) and Alzheimer Disease
(AD). Our dataset included 548 NC, 163 MCI and 549 AD. Since we are using binary
classification methods, we apply the data analysis process for each pair of pathological groups
separately.
5.2.2

Methods
The data analysis process is done in four different steps. In the first step, we use the RuleFit

Algorithm [80] to generate predictive rules of progression to Alzheimer’s Disease. In the second
step, we use the latent trait model [93] in order to weight the detected rules found in Step 1. In
Step 3 we use the Maximum Weighted Multiple Clique Algorithm [94] and select the most
synergistic clique of rules. Finally, in Step 4 we sum up the number of risk increasing rules each
individual matches and subtract the risk decreasing rules that they match from that and calculate a
risk score for each individual. Figure 11 provides a schematic illustration of the data analysis
process. We will describe each step of the process in more detail in future sections.
5.2.2.1

Step 1 – Generating Rules Using RuleFit Algorithm
We are using the RuleFit algorithm [80] to discover rules that are predicting the outcome

of interest, which in our case is progression to Alzheimer’s Disease. Each rule consists of one or
several variables and their ranges. Rulefit is an algorithm that is capable of extracting rules from a
dataset with a large number of variables as discussed in 4.2.5. We defined our rules using single
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variables; in Step 4 of our analysis we try to capture the interaction between variables using the
Maximum Weighted Multiple Clique Problem (MWMCP).
5.2.2.2

Step 2 - Latent Trait Model
Item response theory has been used in psychometrics for measuring various kinds of latent

traits such as ability, intelligence, knowledge, etc. In our problem disease, risk is our latent trait
which is not directly measurable; however, the rules are essentially measurable evidence
associated with the underlying disease risk. There are several functions for modeling latent traits;
we use the logistic function, which has been widely used in the biological sciences to model the
growth of animals and plants. We preferred this model due to its simplicity and since we are
modeling a progression process. The function for the logistic model is shown in Equation 2, in
which

is the disease risk, a is the discrimination parameter and b is the difficulty parameter.
( )=

(

)

(5-1)

Based on the function, we can compute the Item Information curve, which is a measure of
precision and how much information each rule provides. The function for information is shown in
Equation 3
( )=

( )(1 − ( ))

(5-2)

We can get the area under each information curve as

( ) as the information of each

single rule and the non-overlapping area under each pair of curves as the interactive information
from a pair of rules

(

( ( ) , ( )) −

( ( ), ( ))). We use the information that

we calculate at this stage as the weight of each rule in Step 3.
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5.2.2.3

Step 3 - Maximum Weighted Multiple Clique Algorithm
in this step, we use a network-based formulation to select a subset of rules that have the

most synergistic power for differentiating each pair of pathological groups. In this network, each
node represents a potential biomarker and could be weighted by the predictive power of that
biomarker, and the edges between each pair of nodes can be weighted with the synergistic power
of the two biomarkers. We use each node to represent a rule and the edges as the i of each pair of
rules; it should be mentioned that both nodes and edges are binary variables; each node is weighted
by the total area under its information curve, and the edges are weighted by the total of their nonoverlapping area. We use an optimization model developed by [94] which tries to find a clique of
nodes with the maximum total weights of both nodes and edges; they have called this problem a
maximum weighted multiple clique problem (MWMCP). They derived an algorithm that provides
an optimal or near-optimal solution using the column generation method [95,96].
( )

max
. .

≤
≥

1
2

+

≤1

+

+

∀ , ,

∀ , ,

(

∶ > ,

∶ >

+
−1 ∀ , , ∶ >
,
∈ 0,1
∀ , ,
= 1, … ,
= 1, … ,
= 1, … ,
In Equation 4

)

∉
(5-3)

would be 1 if node i is selected in clique k and 0 otherwise and

would be 1 if edge i-j is selected in clique k and 0 otherwise. ( ) is the weight of node i and
(

) is the weight for edge i-j. The constraints in this guarantee that each node belongs to only
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one clique and the variables are binary. The goal in this problem is to find multiple cliques of
nodes with the maximum weight of nodes and edges.
5.2.2.4

Step 4- Finding the Risk Score for Each Individual
In this step rules are labeled as risk-increasing or risk-decreasing based on the number of

individuals in each pathological group of the ones who match each rule. We should mention that
in the RuleFit method, each individual can match more than one rule. The risk score is determined
for each person, by counting the number of risk increasing rules and subtracting the risk-decreasing
rules that they match.

5.3 Results

In the first step we used the RuleFit algorithm to identify rules for each pair of pathological

groups. Table 8, Table 9 and Table 10Table 10 provide the risk-predictive rules identified by the
RuleFit algorithm for each pair of pathological groups. It can be seen that Sit Retrieval test, Trail
timing and Visual Reproduction appeared in all three sets of comparisons. Demographic variables
such as age and number of years of schooling in the US only appeared in comparison of Normal
Controls and MCIs; however, the fact that these rules would lead to an increase or decrease in the
risk of developing AD depends on the cut off values and also the direction of the inequality.
In the second step of our analysis, we coded each rule as a binary variable; if an individual
matched the rule, the rule would be coded as 1 and 0 otherwise. Then we applied item response
theory with a logistic function on the rules. Each rule is used as a risk factor to predict the latent
trait which in our case is the risk of progression to Alzheimer’s disease. The item information
curves for rules are shown in Figure 12 and as described in the methods section, we used the area
under the item information curve as the weight of each rule and the non-overlapping area under
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the item information curve of each pair of rules as the weight of the interaction between each pair
of rules. Plots of item information can be used to see how much information an item contributes.
The adjacency matrix, which includes the weights is the result of Step 2.
In step 3 the adjacency matrix from step 2 is plugged into the MWMCP algorithm and a
set of variables with the maximum synergistic weights are selected. It should be mentioned that at
each iteration of the algorithm, we tuned the threshold for removing insignificant edges in the
model so that the desired number of rules (in our case four) are selected. Since we tried to select
as few rules as possible we changed the threshold so that four rules would be selected at each run.
The top four rules that were selected by the MWMCP to separate the NC from AD were Sit
Retrieval Total Trials 1 - 3 ≤ 20.5 -> AD, Verbal Fluency Total ≥ 9.5 -> NC, Visual Reproduction
Immediate Total Score ≤ 15.5 -> AD, Sit Retrieval Recognition Recall Total ≥ 23.5 -> NC. From
the rules that identify NC and MCI, the top selected rules were Visual Reproduction Delayed Total
Score ≤ 10.5 -> MCI, Sit Retrieval Total Trials 1 - 3 ≤ 19 -> MCI, Number of years of schooling
in U.S. ≥ 17.5 -> NC, Hopkins Verbal Total Trial 1 - 3 ≤ 23.5 -> MCI. And the top four rules that
identify MCI and AD are Sit Retrieval Total Trials 1 - 3 ≥ 18.5 -> MCI, Category Fluency Total
≥ 24.5 -> MCI, Hopkins Verbal Delayed Recall ≤ 2.5 -> AD, Mini Mental State Examination≥
27.5 -> MCI.
Finally, in step 4 we summed up the number of risk increasing rules that each individual
matches and subtracted the number of risk-decreasing rules from that and ended up with a risk
score. We further investigated the risk level of progressing to Alzheimer’s disease for the positive
risk scores versus negative ones. If we categorize individuals with a positive score at higher risk
of AD and the ones with zero or negative score at lower risk of developing AD, we could get a
reasonable level of prediction performance.
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5.4 Conclusion

We tried to summarize a battery of neuropsychological tests with as few tests as possible

and see if instead of 16 different tests, we could use one or two. We found Mini-Mental State
Exam, Hopkins verbal learning, verbal fluency test, Sit retrieval and visual reproduction as the
most important tests in categorizing the subjects. A comparison of the network-based methods
with logistic regression and support vector machines with linear and Gaussian Kernels is provided
in Table 11. The results compare the predictive performance of the network-based model with the
other methods based on the variables selected by our algorithm and also all the 26 variables in the
study. Our network based method, provides acceptable performance in comparison with other
methods and also the models using all variables, except for the case for comparing NC and MCI.
Although in many cases, we can find other methods with better performance, we should consider
the fact that the main goal of our analysis is dimension reduction and selecting a subset of tests
that could lead to an acceptable result.
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Figure 11 Data analysis process

(a) NC-AD

(b) NC-MCI

(c) MCI-AD

Figure 12 Item information curves
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Table 8 Identified rules by RuleFit algorithm for NC-AD pathological groups
Rule 1 (risk increasing rule)
Sit Retrieval Total Trials 1 - 3 ≤ 20.5

Rule 2 (risk increasing rule)
Visual Reproduction Delayed Total Score ≤ 7.5

Category Fluency Total ≤ 33.5
Rule 5 (risk increasing rule)
Visual Reproduction Immediate Total
Score ≤ 15.5
Rule 7 (risk decreasing rule)
Sit Retrieval Recognition Recall Total ≥
23.5
Rule 9 (risk decreasing rule)
Trails B Time ≥ 217.5

Boston Naming Spontaneous (total) ≤ 39.5
Rule 6 (risk decreasing rule)

Rule 3 (risk increasing rule)

Rule 4 (risk increasing rule)

Sit Retrieval bag a 20 min delay ≥ 9.5

Rule 8 (risk decreasing rule)
Wide Range Achievement Test - raw score ≥
40.5
Rule 10 (risk decreasing rule)
Verbal Fluency Total ≥ 9.5

Table 9 Identified rules by RuleFit algorithm for NC-MCI pathological groups
Rule 1 (risk increasing rule)
Visual Reproduction Delayed Total Score ≤
10.5
Rule 3 (risk increasing rule)

Rule 2 (risk increasing rule)

Sit Retrieval bag a 20 min Delay ≤ 6.5

Rule 4 (risk increasing rule)
Wide Range Achievement Test - Raw Score
≤ 49.5
Rule 6 (risk increasing rule)
Hopkins Verbal Total Trial 1 - 3 ≤ 23.5
Rule 8 (risk decreasing rule)
Trails A Time ≤ 36.5
Rule 10 (risk decreasing rule)
Number of years of schooling in U.S. ≥ 17.5

Sit Retrieval Total Trials 1 - 3 ≤ 19.5

Rule 5 (risk increasing rule)
Trails B Time ≤ 93.5
Rule 7 (risk decreasing rule)
Boston Naming Spontaneous (total) ≥ 47.5
Rule 9 (risk decreasing rule)
Age ≤ 72.5

Table 10 Identified rules by RuleFit algorithm for MCI-AD pathological groups
Rule 1 (risk increasing rule)
Visual Reproduction Delayed Total Score ≤
7.5
Rule 3 (risk increasing rule)
Digit Symbol ss ≤ 10.5
Rule 5 (risk increasing rule)
Verbal Fluency Total ≤ 20.5
Rule 7 (risk decreasing rule)
Sit Retrieval Total Trials 1 - 3 ≥ 18.5
Rule 9 (risk decreasing rule)
Boston Naming Spontaneous (total) ≥ 38.5

Rule 2 (risk increasing rule)

Sit Retrieval Bag a 20 min Delay ≥ 2.5
Rule 4 (risk increasing rule)
Hopkins Verbal Delayed Recall ≤ 2.5
Rule 6 (risk increasing rule)
Category Fluency Total ≤ 24.5
Rule 8 (risk decreasing rule)
Trails B Time ≤ 285.5
Rule 10 (risk decreasing rule)
Mini Mental State Examination≥ 27.5

62

Table 11 Predictive performance of the network based model compared to available methods
Selected Variables by All 26 Variables
Network-based

Network-Based
SVM (linear)
SVM (Gaussian)
Logistic
Regression
SVM (linear)
SVM (Gaussian)
Logistic
Regression

NC - AD
ACC Sen
0.93 0.91
0.915 0.87
0.95 0.92
0.92

0.88

0.97

Spec
0.96
0.97
0.97

NC - MCI
ACC Sen Spec
0.84 0.52 0.97
0.78 0.27 0.92
0.82 0.36 0.96

ACC
0.78
0.72
0.76

0.94

NC - AD
ACC Sen Spec
0.9
0.97 0.66
0.98 0.97 0.96

0.59

0.93

NC - MCI
ACC Sen Spec
0.76 0.95 0.85
0.83 0.92 0.64

MCI-AD
ACC Sen
Spec
0.87
0.90
0.78
0.98
0.85
0.77

0.96

0.79

0.96

0.87

0.91

63

0.85

Spec
0.83
0.48
0.57

0.85

0.94

0.76

MCI-AD
Sen
0.76
0.82
0.84

0.70

0.51

0.86

CHAPTER 6: SUMMARY
In this dissertation we applied rule-based analysis on medical data and tried to extract
predictive rules out of large and inter-correlated data. Our methods were easy to implement, and
the comparison of our results with current machine learning methods showed reasonable predictive
performance.
First, we developed decision tree models on ADNI dataset and extracted rules out of it to
predict elevated brain amyloid level, which is the first and most important symptom of Alzheimer’s
Disease onset. The current diagnostic methods for Alzheimer’s disease are expensive and not
available in all clinics. We predicted the amyloid level using blood proteomics and
neuropsychological tests, which are inexpensive and available in all clinics. We have published a
paper on this study in collaboration with Byrd Alzheimer’s Institute in the Journal of Alzheimer’s
Disease [1].
Second, we tried to compare the interaction of plasma biomarkers of Alzheimer’s in three
different female ethnic groups. We applied decision tree models and extracted predictive rules of
Alzheimer’s disease for each ethnicity. Few studies have targeted pathological, cardiovascular and
inflammatory biomarkers in plasma at the same time. We have submitted a manuscript on this
study in the Journal of Alzheimer’s Disease in collaboration with the Byrd Alzheimer’s institute.
In our third study, we used the RuleFit algorithm and tried to identify homogeneous
subgroups out of a population who participated in a pediatric study. We detected eight rules which
characterized eight different subpopulations in the participants. We compared our results with a
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previous regression model applied on the same dataset. We have submitted a manuscript on this
study to the Scientific Reports Journal.
Finally, we did a redundancy analysis on a battery of neuropsychological tests from
Alzheimer’s Disease Research Center (ADRC). We used the RuleFit algorithm for extracting rules
out of the dataset and applied Maximum Weighted Multiple Clique Problem (MWMCP) to select
a clique of the rules with the maximum weight. The Latent trait model was used to weight the
rules. As a result, we found five tests which could result in the same conclusion about the
pathological group of the patients instead of using the full suite of tests.
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